NewGenIvf Group Limited (NIVF)
USD 0.33
(-23.27%)
USD 0.33
(-23.27%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 5.13 Million | 5.94 Million | 4.11 Million |
| Cost of Revenue | 3.45 Million | 4.4 Million | 3.09 Million |
| Gross Profit | 1.68 Million | 1.53 Million | 1.02 Million |
| Operating Expenses | 2.52 Million | 504.9 Thousand | 826.02 Thousand |
| Selling, General and Administrative Expenses | 2.52 Million | 504.9 Thousand | 826.02 Thousand |
| Research and Development Expenses | - | - | - |
| Other Expenses | - | 23.01 Thousand | 45.65 Thousand |
| Cost and Expenses | 5.09 Million | 504.9 Thousand | 3.91 Million |
| Operating Income | 42.24 Thousand | -504.9 Thousand | 198.75 Thousand |
| Interest Expense | 46.17 Thousand | 77.75 Thousand | 88.28 Thousand |
| Income Tax Expense | -799.26 Thousand | 208.14 Thousand | 294.71 Thousand |
| Earnings before Tax | -690.85 Thousand | 500.65 Thousand | 156.18 Thousand |
| Net Income | -690.85 Thousand | 458.66 Thousand | -533.00 |
| Earnings Per Share Basic | -0.13 | 0.06 | -0.00 |
| Earnings Per Share Diluted | -0.13 | 0.06 | -0.00 |
| Weighted Average Shares Outstanding | 5.43 Million | 7.74 Million | 10.14 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.43 Million | 7.74 Million | 10.14 Million |
| Gross Margin | 0.33 | 0.26 | 0.25 |
| EBIT Margin | -0.49 | -0.08 | 0.14 |
| Profit Margin | -0.13 | 0.08 | -0.00 |
| EBITDA | -2.52 Million | -504.9 Thousand | 587.01 Thousand |
| Earnings Before Tax Margin | 0.01 | -0.08 | 0.05 |
| Breakdown | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Revenue | 5.13 Million | - | - | - | - | 5.94 Million |
| Cost of Revenue | 3.45 Million | - | - | - | - | 4.4 Million |
| Gross Profit | 1.68 Million | - | - | - | - | 1.53 Million |
| Operating Expenses | 2.52 Million | 1.26 Million | 377.71 Thousand | 366.99 Thousand | 510.54 Thousand | 504.9 Thousand |
| Selling, General and Administrative Expenses | - | 1.26 Million | 377.71 Thousand | 366.99 Thousand | 510.54 Thousand | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 111.83 Thousand | - | - | - | - | 23.01 Thousand |
| Cost and Expenses | 2.52 Million | 1.26 Million | 377.71 Thousand | 366.99 Thousand | 510.54 Thousand | 504.9 Thousand |
| Operating Income | -2.52 Million | -1.26 Million | -377.72 Thousand | -367 Thousand | -510.54 Thousand | -504.9 Thousand |
| Interest Expense | 46.17 Thousand | - | - | - | - | 77.75 Thousand |
| Income Tax Expense | -229.7 Thousand | - | - | - | - | 208.14 Thousand |
| Earnings before Tax | -690.85 Thousand | -955.48 Thousand | 127.02 Thousand | 85.49 Thousand | 52.12 Thousand | 500.65 Thousand |
| Net Income | -690.85 Thousand | -955.48 Thousand | 127.02 Thousand | 85.49 Thousand | 52.12 Thousand | 458.66 Thousand |
| Earnings Per Share Basic | - | -0.26 | 0.02 | 0.02 | 0.01 | - |
| Earnings Per Share Diluted | - | -0.26 | 0.02 | 0.02 | 0.01 | - |
| Weighted Average Shares Outstanding | 5.43 Million | 3.72 Million | 5.42 Million | 5.42 Million | 5.42 Million | 7.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 5.43 Million | 3.72 Million | 5.42 Million | 5.42 Million | 5.42 Million | 7.74 Million |
| Gross Margin | 0.33 | - | - | - | - | 0.26 |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | -0.13 | - | - | - | - | 0.08 |
| EBITDA | - | -1.26 Million | -377.72 Thousand | -367 Thousand | -510.54 Thousand | - |
| Earnings Before Tax Margin | -0.49 | - | - | - | - | -0.08 |
WWL
BIOSGN
3073
300940
AHX
600845